MediPharm Labs to Present at the 31st Annual ROTH Conference
March 12 2019 - 3:18PM
MediPharm Labs Corp. (TSXV: LABS) (OTCQB: MLCPF) (FSE:MLZ)
(“MediPharm Labs”), a leader in specialized, research-driven
cannabis extraction, distillation, purification and cannabinoid
isolation, today announces that it will present at the 31st Annual
ROTH Conference in Orange County, California.
MediPharm Labs executive management is scheduled
to present at the conference on Tuesday, March 19, at approximately
8:00 a.m. PDT at The Ritz-Carlton hotel in Dana Point.
The annual ROTH Conference, hosted by ROTH
Capital Partners March 17-19, gathers more than 500 companies and
approximately 1,000 investors, featuring presentations from public
and private companies in a variety of sectors including
healthcare.
About MediPharm Labs
Corp.Founded in 2015, MediPharm Labs has the distinction
of being the first company in Canada to become a licensed producer
for cannabis oil production under the ACMPR without first receiving
a cannabis cultivation licence. This expert focus on cannabis
concentrates from our cGMP (current Good Manufacturing Practices)
and ISO standard clean rooms and critical environments laboratory,
allows MediPharm Labs to produce purified, pharmaceutical-grade
cannabis oil and concentrates for advanced derivative products.
MediPharm Labs has invested in an expert, research-driven team,
state-of-the-art technology, downstream extraction methodologies
and purpose-built facilities to deliver pure, safe and
precisely-dosed cannabis products to patients and consumers.
MediPharm Labs’ private label program is a high margin business for
the Company, whereby it opportunistically procures dry cannabis
flower and trim from its numerous product supply partners, to
produce proprietary cannabis oil concentrate products for resale
globally on a private label basis. MediPharm Labs was recently
named START-UP OF THE YEAR at the Canadian Cannabis Awards.
Through its subsidiary, MediPharm Labs Australia
Pty. Ltd., MediPharm has also completed its application process
with the federal Office of Drug Control to extract and import
medical cannabis products in Australia.
For further information, please
contact:Laura Lepore, Vice President, Investor Relations
& CommunicationsTelephone: 705-719-7425 ext
216Email: investors@medipharmlabs.comWebsite: www.medipharmlabs.com
NEITHER THE TSX VENTURE EXCHANGE NOR ITS
REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE
POLICIES OF THE TSXV) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR
ACCURACY OF THIS RELEASE.
MediPharm Labs (TSXV:LABS)
Historical Stock Chart
From Aug 2024 to Sep 2024
MediPharm Labs (TSXV:LABS)
Historical Stock Chart
From Sep 2023 to Sep 2024